Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistNephron SC Inc., a pharmaceutical company, received a Warning Letter from the FDA on September 22, 2020, regarding drug products. Due to limited metadata availability, the specific nature of the violations cannot be determined from this summary alone; however, the warning indicates significant regulatory concerns that warrant review of the complete FDA correspondence. This letter falls under the FDA's drug product regulatory authority and represents a formal enforcement action requiring company response and corrective action.